Document series
Trial abstracts — page 8
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 8 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| ESSENCE-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| ESSENCE-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| EXENATIDE-GE-PD-DDIprogramme record | Exenatide | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| EXENATIDE-GE-PD-HEPATIC-IMPprogramme record | Exenatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| GLORY-1-OLEprogramme record | Mazdutide | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| GLORY-1-QOLprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-1-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-1-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-ADHERENCEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Observational | — | 2025 | Very low |
| REDEFINE-2-BIOMARKERprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-ELDERLYprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| REDEFINE-2-OLEprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| SOUL-DDIprogramme record | Semaglutide, oral | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| SOUL-HEPATIC-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SOUL-PKprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SOUL-RENAL-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| STRIDE-QOLprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| STRIDE-REGIONAL-CNprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| STRIDE-REGIONAL-JPprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURMOUNT-5-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SURMOUNT-KOA-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| SURMOUNT-KOA-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
page 8 of 30